The analyses of TCGA database revealed that matiptase is down-regulated in the high-risk group with a low survival rate in lung adenocarcinoma patients (Supplementary Figure S3A), while hepsin levels is not relevant with the lung cancer patients’ survival (both low-risk and high-risk groups have a similar survival rate, Supplementary Figure S3B). Here, HPN is linked to lung carcinoma.